Page 2 of 3
Progress in the implementation of Label-Free Dectetion - part 1: cell-based assays: Fall 08by Dr John Comley Overall it remains unclear whether label-free will break into main stream cell-based lead discovery or will mostly fill the gaps that other technologies do less well?
|
Growing Interest in Outsourcing Ion Channel Services; Summer 08By Dr John Comley Significant demand now exists in Pharma and Biotech to access ion channel testing services and this is reflected by the number and the variety of service offerings.
|
Challenges in transferring bioanalytical methods; Fall 08By Dr Chris Beaver Drug development is arduous and expensive with any delay to market resulting in significant financial impact. Delays at any stage of the process cause challenges to programmes, however, s...
|
The role of Thorough QT testing in managing drug development: Winter 07By Dr William S. Wheeler With few exceptions, all compounds being submitted to the Food and Drug Administration (FDA) for approval in the United States will require an assessment of QT prolongation, either by a s...
|
Perspectives for ADME/Tox Integration in the Discovery Process; Winter 07By Dr Constance Höfer ADME/T is a relatively new ‘symbiotic’ acronym for the investigation of basic compound behaviour in terms of absorption, distribution, metabolism and excretion, combined with assessme...
|
Dispense and Imaging Assays: Spring 08By Dr John Comley Progress towards the uptake and adoption of flash luminescence readouts in screening were the subject of HTStec’s recent Dispense & Imaging (D&I) Trends 2007 report. The report suggests...
|
Where the (drug) action really is; progress in systems-based analysis of Cellular Signalling; Spring 08By Dr Jeffrey A. Radding Drug discovery currently focuses on targeted approaches, relying on validation of the target as a disease driver. However, the underlying biological complexity of disease often frustrates...
|
Déjà vu all over again: emerging concepts of G protein-coupled receptor (GPCR) function and drug discovery; Winter 06By Dr Richard M. Eglen, Dr Roger Bossé and Dr Graham S. Long; Winter 06 G protein-coupled cell surface receptors (GPCRs) have served a fundamental role in modern pharmacology, due to their central importance in cell communication, and have been the target for...
|
Page 2 of 3
|
|
